Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Unilever plc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Unilever plc trades at $64.09 (market cap $134.00B). The key difference: Unilever plc is far larger — about 4.3× GE HealthCare Technologies Inc. Common Stock's market cap, and Unilever plc pays the higher dividend (3.4%). Which is the better fit depends on your goals.
| GEHC | UL | |
|---|---|---|
Market Cap | $31.07B | $134.00B |
Volume | 3,443,020 | 2,393,833 |
Sector | Health | Consumer Staples |
52-Week High | $88.16 | $74.59 |
52-Week Low | $59.48 | $55.05 |
Enterprise Value | $39.53B | $158.93B |
Dividend Yield | 0.23% | 3.4% |
Typical Hold Time | — | 112 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Unilever (UL) trades at $63.86, up 1.45% on the day, with a bullish technical signal and strong profitability metrics including a 18.32% net income margin and 54.56% ROE. Recent earnings have consistently missed expectations, but the company is undergoing strategic portfolio streamlining, including a planned $65 billion food business merger with McCormick, which is under regulatory scrutiny. Cash flow from operations remains robust at $8.35 billion for 2025, though net cash flow was negative $2.08 billion due to significant investing and financing outflows.
The outlook is mixed: analyst consensus is a 'Hold' with a $66.08 price target, suggesting modest upside, but risks include execution of the McCormick deal, competitive pressures, and recent earnings misses. The stock's valuation at a P/E of 21.87 appears reasonable given its defensive emerging market exposure and high margins, but investor sentiment is cautious pending clearer signs of sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
